
The prevalence of metabolic syndrome (MS), which mainly includes hypertension, hyperglycemia, and hyperlipidemia, remains high, and the safety and antibody response of inactivated coronavirus disease 2019 (COVID-19) vaccination in patients with metabolic syndrome (MS) is still inconsistent. Therefore it is necessary to explore the safety and antibody responses of inactivated COVID-19 vaccination in MS patients in clinical practice. The study findings showed that inactivated COVID-19 vaccines were well-tolerated but induced a poorer antibody response against SARS-CoV-2 in MS patients compared to health control (HC) participants. Patients with MS should therefore be more proactive in receiving inactivated COVID-19 vaccine, and a booster vaccination may be considered necessary.
Like
Save
Share